Compounds for the treatment of metabolic disorders
Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
1. A compound of the formula:
wherein
n is 1 or 2;
t is 0 or 1;
m is 0 and r is 1, or m is 1 and r is 0;
A is a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula II by a ring carbon;
Z is
R 1 is hydrogen or alkyl having from 1 to 7 carbon atoms;
R 4 is hydrogen; —NHCOOC(CH 3 ) 3 ; —NHCH 3 ; or —NHCH 2 CH 3 ;
or when R 1 is hydrogen, a pharmaceutically acceptable salt of the compound.
2. A compound of the formula:
wherein
n is 1 or 2;
R 1 is hydrogen or alkyl having from 1 to 7 carbon atoms;
R 14 is hydroxy or hydrogen; and
A is a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula V′ by a ring carbon;
or a pharmaceutically acceptable salt of the compound.
3. The compound of claim 2 , represented by the formula:
wherein
n is 1 or 2;
R 1 is hydrogen or alkyl having from 1 to 7 carbon atoms;
A is a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula V by a ring carbon;
or a pharmaceutically acceptable salt of the compound.
4. A compound of the formula:
wherein
n is 1 or 2;
R 1 is hydrogen or alkyl having from 1 to 3 carbon atoms; and
A is a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula XCI by a ring carbon;
or a pharmaceutically acceptable salt of the compound.
5. A compound of the formula:
wherein
n is 1 or 2;
R 1 is hydrogen or alkyl having from 1 to 3 carbon atoms; and
A is a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula CXVI by a ring carbon;
or a pharmaceutically acceptable salt of the compound.
6. A compound of the formula:
wherein
n is 0, 1 or 2;
R 1 is hydrogen or alkyl having from 1 to 3 carbon atoms;
R 15 is hydrogen or alkyl having from 1 to 3 carbon atoms;
R 9 is hydrogen, halo, hydroxy, or alkoxy having from 1 to 3 carbon atoms;
A is a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon;
or a pharmaceutically acceptable salt of the compound.